The size of the Europe Ophthalmology Therapeutics Market was worth USD 6.44 billion in 2020. It is further estimated to be growing at a CAGR of 6.9% and value USD 8.98 billion by 2025.
The market is showing evident potential in the mentioned forecast period. Ophthalmology deals with the treatment of eye defects and diseases. Age-related macular degeneration is the major cause of visual loss in adults in industrialized countries; other conditions associated with vision loss include cataracts, diabetic retinopathy, and glaucoma, along with the low vision.
There are around 25 million people with visual impairment in Europe. It is estimated that more than 70 million people have eye diseases that are in the early stages which if left untreated may lead to severe impairment.
Europe Ophthalmology Therapeutics is driven by the increasing incidence of vision impairment. Advancements in technology in the field of medicine are also playing a key role in the growth of the market. The growing geriatric population across the continent along with an increase in disposable income of the people are some of the factors adding up to the market growth.
However, stringent regulatory framework and unclear reimbursement policies are also acting as hurdles for market growth. Lack of awareness about various diseases associated with ophthalmology is also a major restraint hindering the market growth.
This research report on the European Ophthalmology Therapeutics Market has been segmented and sub-segmented the Market into the following categories:
By Indication:
By End User:
By Country:
Geographically, Within Europe, Germany is the largest market for Ophthalmology Therapeutics Glaucoma is the largest indication segment accounting for a share of approximately 31% followed by AMD with a share of XX%.
Companies playing a leading role in the European Ophthalmology Therapeutics Market are Pfizer Inc., Allergan Inc., Alcon Inc., Merck & co. Inc., Roche Valeant, Regeneron, Santen, Bayer, Senju, Lpath and Eye Gate Pharmaceuticals.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Indication
5.1.1 Glaucoma
5.1.2 Dry Eye Syndrome
5.1.3 Diabetic Retinopathy
5.1.4 Retinal Vein Occlusion
5.1.5 Age-Related Macular Degeneration (AMD)
5.1.6 Macular Edema
5.1.7 Allergic Conjunctivitis
5.2 By End User
5.2.1 Hospitals
5.2.2 Eye Clinics
5.2.3 Diagnostic Centers
5.2.4 Patients
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 Allergan, Inc.
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 Merck & Co Inc
9.3 Pfizer
9.4 Roche
9.5 Novartis (Alcon)
9.6 Valeant
9.7 Regeneron
9.8 Santen
9.9 Bayer
9.10 Senju
9.11 Lpath
9.12 Eye Gate Pharmaceuticals
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Market Outlook & Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
